Browsing Centre for Experimental Medicine and Rheumatology (EMR) by Author "Ho, P"
Now showing items 1-5 of 5
-
O07 Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy
Humby, FC; Lewis, M; Durez, P; Buch, MH; Bombardieri, M; Rizvi, H; Rivellese, F; Fossati, L; Hands, R; Giorli, G (2020-04-01) -
A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response - Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy
Humby, F; Buch, MH; Durez, P; Lewis, M; Bombardieri, M; Rizvi, H; Kelly, S; Fosatti, L; Hands, R; Giorli, G (2019-10) -
RANDOMISED, OPEN LABELLED CLINICAL TRIAL TO INVESTIGATE SYNOVIAL MECHANISMS DETERMINING RESPONSE: RESISTANCE TO RITUXIMAB VERSUS TOCILIZUMAB IN RA PATIENTS FAILING TNF INHIBITOR THERAPY
Humby, FC; Lewis, M; Durez, P; Buch, MH; Bombardieri, M; Rizvi, H; Rivellese, F; Fossati, L; Hands, R; Giorli, G (2020-04) -
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby, F; Durez, P; Buch, MH; Lewis, MJ; Rizvi, H; Rivellese, F; Nerviani, A; Giorli, G; Mahto, A; Montecucco, C (2021-01-23)BACKGROUND: Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more ... -
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
Rivellese, F; Nerviani, A; Giorli, G; Warren, L; Jaworska, E; Bombardieri, M; Lewis, MJ; Humby, F; Pratt, AG; Filer, A (2023-11-01)Background: Despite highly effective targeted therapies for rheumatoid arthritis, about 40% of patients respond poorly, and predictive biomarkers for treatment choices are lacking. We did a biopsy-driven trial to compare ...